top of page

Technology

 

SimplifiDx Molecular is in development and is not FDA-cleared or available for sale.

 

SimplifiDx Molecular pairs a reusable handheld reader with a single-use test. The reader runs PCR on the device and shows the result on screen, with no lab, phone or internet needed.

 

How a test runs: collect the sample, insert the test, read the result.

 

Development target: about 30 minutes from sample to result.

 

Pipeline

Development pipeline, from earlier to later stages. Earlier program: COVID-19, Flu A and B antigen version developed in the NIH RADx program. In development: Hepatitis B and C, lead program. Next: drugs of abuse. Roadmap: STIs, women's health, HIV, RSV, tuberculosis, veterinary, global Ebola and Marburg. Exploratory: Lyme disease.
bottom of page